Nonalcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide and affects approximately one third of adults in the United States. The disease is becoming a global epidemic as a result of the rising rates of obesity and metabolic disease. Emerging data suggest weight loss of ≥10% overall body weight is beneficial in resolving steatosis and reversing fibrosis. Prospective trials comparing various diets are limited by lack of sufficient power as well as pre- and post-treatment histopathology, and therefore no specific diet is recommended at this time. In this narrative review we examine the pathophysiology behind specific macronutrient components that can either promote or reverse NAFLD to help inform more specific dietary recommendations. Overall, the data supports reducing saturated fat, refined carbohydrates, and red and processed meats in the diet, and increasing the consumption of plant-based foods. Diets that incorporate these recommendations include plant-based diets such as the Dietary Approaches to Stop Hypertension, Mediterranean, vegetarian, and vegan diets.
Citations
Citations to this article as recorded by
Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards Faisal Abaalkhail, Faisal M. Sanai, Khalid AlSwat, Adnan Alzanbagi, Ahmed Aljedai, Ali Alshehri, Assim Alfadda, Hamdan Alghamdi, Majid Almadi, Mohammad Aleissa, Mona Ismail, Saud Alsifri, Turki Alzahrani, Saleh Alqahtani, Waleed Al Hamoudi Saudi Journal of Gastroenterology.2026; 32(2): 104. CrossRef
Exploring the relationship between nutritional status, body composition and health-related quality of life in non-alcoholic fatty liver disease Aiman Khan, Aisha Perveen, Neetu Bansal, Sadia Chishty Nutrition & Food Science.2026; 56(1): 96. CrossRef
The Metabolic Dysfunction–Associated Steatotic Liver Disease–CKD Axis: Intersecting Pathways and Opportunities for Early Intervention Sriram Sriperumbuduri, Prathab Balaji Saravanan, Gaurav Gupta, Arun J. Sanyal Kidney International Reports.2026; 11(4): 103757. CrossRef
A bio-fortified whole tomato food supplement as potential dietary tool for the management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Pier Giorgio Natali, Luisa Imberti, Mauro Piantelli, Marco Minacori, Alessandra Sottini, Erica Gianazza, Cristina Banfi Journal of Translational Medicine.2026;[Epub] CrossRef
Plant-Based and Vegetarian Diets for Weight Loss: A Scoping Review with ☸️SAIMSARA
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH) Albert Do, Frhaan Zahrawi, Wajahat Z. Mehal Nature Reviews Drug Discovery.2025; 24(3): 171. CrossRef
Effectiveness of RESET care program: A real-world-evidence on managing non-alcoholic fatty liver disease through digital health interventions Jayesh Soni, Nikhilesh Pathak, Mihir Gharia, Devina Aswal, Jaymin Parikh, Prachi Sharma, Astha Mishra, Dhvni Lalan, Twinkle Maheshwari World Journal of Hepatology.2025;[Epub] CrossRef
Evaluating the impact of the Dietary Approaches to Stop Hypertension diet versus a calorie‐restricted diet on metabolic dysfunction‐associated steatotic liver disease: A meta‐analysis of randomized controlled trials Fariha Hasan, Avneet Singh, Alexander Garcia, Syeda Hafsa Qadri, Hina Sattar, Rimmel Ali, Hassam Ali, Tommy Nguyen, Babu P. Mohan, Krysta Contino Hepatology Research.2025; 55(4): 515. CrossRef
Liver-related Events and Outcomes in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease Varies With the Type of Cardiometabolic Risk Factor Shekhar Swaroop, Sagnik Biswas, Shubham Mehta, Arnav Aggarwal, Umang Arora, Samagra Agarwal, Amitkumar Chavan, Baibaswata Nayak, Shalimar Journal of Clinical and Experimental Hepatology.2025; 15(5): 102559. CrossRef
Evaluating the RESET care program: Advancing towards scalable and effective healthcare solutions for metabolic dysfunction-associated liver disease Mariana M Ramírez-Mejía, Froylan D Martínez-Sánchez, Jacqueline Córdova-Gallardo, Nahum Méndez-Sánchez World Journal of Hepatology.2025;[Epub] CrossRef
Dietary Intake of Major Minerals and Trace Elements in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: Implications for Dietary Intervention Vasily Isakov, Armida Sasunova, Sergey Morozov, Alexei Goncharov Advances in Therapy.2025; 42(7): 3486. CrossRef
Evidence‐based review of the nutritional treatment of obesity and metabolic dysfunction‐associated steatotic liver disease in children and adolescents Sara Karjoo, Amy Braglia‐Tarpey, Alvin P. Chan, Ana Gabriela Ayala Germán, Rachel E. Herdes, Nikhil Pai, Desiree Sierra‐Velez, Bridget Whitehead, Ruben E. Quiros‐Tejeira, Debora Duro Journal of Pediatric Gastroenterology and Nutrition.2025; 81(3): 485. CrossRef
Emerging therapies and real-world application of metabolic dysfunction-associated steatotic liver disease treatment Hee Yeon Kim, Mary E. Rinella Clinical and Molecular Hepatology.2025; 31(3): 753. CrossRef
Barriers and facilitators to non-pharmacological management of metabolic dysfunction-associated steatotic liver disease: a qualitative evidence synthesis Yusuf Yilmaz Frontiers in Pharmacology.2025;[Epub] CrossRef
The impact of food insecurity on chronic liver disease: A systematic review of the literature Laila M. Elias, Jordy E. Agins, David S. Goldberg, Therese Bittermann, Elena Byhoff Hepatology Communications.2025;[Epub] CrossRef
Gut microbiota heterogeneity in non-alcoholic fatty liver disease: a narrative review of drivers, mechanisms, and clinical relevance Ying Guo, Naisi Zhang, Dongmei Pei Frontiers in Microbiology.2025;[Epub] CrossRef
Gender Differences in Healthy Eating Index as Informed by the Awareness of Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease Wei-Ting Lin, Madeline Novack, Suthat Liangpunsakul, Chiung-Kuei Huang, Hui-Yi Lin, Po-Hung Chen, Tung-Sung Tseng, Peng-Sheng Ting Livers.2025; 5(4): 61. CrossRef
A Novel Prescription Digital Therapeutic Option for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease Naim Alkhouri, Katherine Edwards, Mark Berman, Heather Finn, Rafael Escandon, Paul Lupinacci, Nicole Guthrie, Angie Coste, Jesus Topete, Mazen Noureddin Gastro Hep Advances.2024; 3(1): 9. CrossRef
The effects of meal patterns on liver steatosis, fibrosis, and biochemical factors in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial Mohammad Alizadeh, Mohammadreza Mohammad Hosseiniazar, Farkhondeh Alami, Somayyeh Bararnia Adabi Journal of Diabetes & Metabolic Disorders.2024; 23(1): 987. CrossRef
Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population Carolin V. Schneider, Kai Markus Schneider, Anastasia Raptis, Helen Huang, Christian Trautwein, Rohit Loomba Alimentary Pharmacology & Therapeutics.2024; 59(10): 1271. CrossRef
Manipulating the Gut Microbiome to Alleviate Steatotic Liver Disease: Current Progress and Challenges Ernesto Saenz, Nathally Espinosa Montagut, Baohong Wang, Christoph Stein-Thöringer, Kaicen Wang, Honglei Weng, Matthias Ebert, Kai Markus Schneider, Lanjuan Li, Andreas Teufel Engineering.2024; 40: 51. CrossRef
Innovative treatments for obesity and NAFLD: A bibliometric study on antioxidants, herbs, phytochemicals, and natural compounds Salvatore Pezzino, Maria Sofia, Chiara Mazzone, Giorgia Litrico, Luigi Piero Greco, Luisa Gallo, Gaetano La Greca, Saverio Latteri Heliyon.2024; 10(16): e35498. CrossRef
Machine learning uncovers manganese as a key nutrient associated with reduced risk of steatotic liver disease Simon Schophaus, Kate Townsend Creasy, Paul‐Henry Koop, Jan Clusmann, Julius Jaeger, Varnitha Punnuru, Alexander Koch, Christian Trautwein, Rohit Loomba, Tom Luedde, Kai Markus Schneider, Carolin V. Schneider Liver International.2024; 44(10): 2807. CrossRef
Dietary Approaches to Stop Hypertension (DASH) and mortality risk among patients with liver cirrhosis: a prospective cohort study Aida Zarei, Fereshteh Pashayee-khamene, Azita Hekmatdoost, Sara Karimi, Saleheh Ahmadzadeh, Mehdi Saberifiroozi, Behzad Hatami, Zahra Yari BMC Research Notes.2024;[Epub] CrossRef
Common Bean Suppresses Hepatic Ceramide Metabolism in a Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease Vanessa K. Fitzgerald, Tymofiy Lutsiv, John N. McGinley, Elizabeth S. Neil, Mary C. Playdon, Henry J. Thompson Nutrients.2024; 16(18): 3196. CrossRef
Non‐alcoholic fatty liver disease: The importance of physical activity and nutrition education—A randomized controlled study Diler Us Altay, Yasemin Kaya, Duygu Mataraci Değirmenci, Emine Kocyiğit, Abdullah Üner, Tevfik Noyan Journal of Gastroenterology and Hepatology.2024; 39(12): 2723. CrossRef
Prevalence of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Persons with Obesity and Type 2 Diabetes Mellitus: A Cross-sectional Study Saba Latif, Tasnim Ahsan Euroasian journal of hepato-gastroenterology.2024; 14(2): 129. CrossRef
Exosomal RBP4 potentiated hepatic lipid accumulation and inflammation in high-fat-diet-fed mice by promoting M1 polarization of Kupffer cells Jin-Mei Yao, Hua-Zhong Ying, Huan-Huan Zhang, Fen-Sheng Qiu, Jun-Qi Wu, Chen-Huan Yu Free Radical Biology and Medicine.2023; 195: 58. CrossRef
Screening and interventions to prevent nonalcoholic fatty liver disease/nonalcoholic steatohepatitis-associated hepatocellular carcinoma Simona Cernea, Danusia Onișor World Journal of Gastroenterology.2023; 29(2): 286. CrossRef
Multi-omics analysis of the effects of dietary changes and probiotics on diet-induced obesity Shiman Jiang, Yuanshuai Su, Qiangqiang Wang, Longxian Lv, Chen Xue, Lvwan Xu, Lanjuan Li Current Research in Food Science.2023; 6: 100435. CrossRef
Positive association between nonalcoholic fatty liver disease and growth hormone deficiency in patients with nonfunctioning pituitary adenoma Yoon-a Hwang, Hye Won Lee, Sang Hoon Ahn, Eun Jig Lee, Cheol Ryong Ku, Seung Up Kim Frontiers in Endocrinology.2023;[Epub] CrossRef
Correspondence on Letter regarding “The usefulness of metabolic score for insulin resistance for the prediction of incident non-alcoholic fatty liver disease in Korean adults” Jun-Hyuk Lee, Kyongmin Park, Hye Sun Lee, Hoon-Ki Park, Jee Hye Han, Sang Bong Ahn Clinical and Molecular Hepatology.2023; 29(1): 179. CrossRef
Effect of exercise-based interventions in nonalcoholic fatty liver disease: A systematic review with meta-analysis Heechul Nam, Jeong-Ju Yoo, Yuri Cho, Seong Hee Kang, Sang Bong Ahn, Hye-Won Lee, Dae Won Jun, Do Seon Song, Miyoung Choi Digestive and Liver Disease.2023; 55(9): 1178. CrossRef
Bariatric surgery for non-alcoholic fatty liver disease: Indications and post-operative management Anja Geerts, Sander Lefere Clinical and Molecular Hepatology.2023; 29(Suppl): S276. CrossRef
Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future Asako Nogami, Masato Yoneda, Michihiro Iwaki, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Kento Imajo, Satoru Saito, Atsushi Nakajima Clinical and Molecular Hepatology.2023; 29(Suppl): S123. CrossRef
Pharmacological advances in the treatment of nonalcoholic fatty liver diseases : focused on global results of randomized controlled trials Jihyun An, Joo Hyun Sohn Clinical and Molecular Hepatology.2023; 29(Suppl): S268. CrossRef
The independent effect of exercise on biopsy proven non-alcoholic fatty liver disease: A systematic review Young-Joo Jin Clinical and Molecular Hepatology.2023; 29(2): 414. CrossRef
The growing burden of non-alcoholic fatty liver disease on mortality Ju-Yeon Cho, Won Sohn Clinical and Molecular Hepatology.2023; 29(2): 374. CrossRef
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990–2019: A DALY-based analysis of the Global Burden of Disease 2019 study Sungchul Choi, Beom Kyung Kim, Dong Keon Yon, Seung Won Lee, Han Gyeol Lee, Ho Hyeok Chang, Seoyeon Park, Ai Koyanagi, Louis Jacob, Elena Dragioti, Joaquim Radua, Jae Il Shin, Seung Up Kim, Lee Smith Clinical and Molecular Hepatology.2023; 29(2): 433. CrossRef
Gut Microbiome in the Progression of NAFLD, NASH and Cirrhosis, and Its Connection with Biotics: A Bibliometric Study Using Dimensions Scientific Research Database Salvatore Pezzino, Maria Sofia, Chiara Mazzone, Sergio Castorina, Stefano Puleo, Martina Barchitta, Antonella Agodi, Luisa Gallo, Gaetano La Greca, Saverio Latteri Biology.2023; 12(5): 662. CrossRef
PNPLA3 GENE POLYMORPHISM AND RED MEAT CONSUMPTION INCREASED FIBROSIS RISK IN NASH BIOPSY-PROVEN PATIENTS UNDER MEDICAL FOLLOW-UP IN A TERTIARY CENTER IN SOUTHWEST BRAZIL Silvia Massami YOSHIMURA, Sebastião Mauro Bezerra DUARTE, José Tadeu STEFANO, Daniel Ferraz de Campos MAZO, João Renato Rebello PINHO, Claudia P OLIVEIRA Arquivos de Gastroenterologia.2023; 60(1): 98. CrossRef
Plasma Fatty Acid Composition, Oxidative and Inflammatory Status, and Adherence to the Mediterranean Diet of Patients with Non-Alcoholic Fatty Liver Disease Margalida Monserrat-Mesquida, Maria Magdalena Quetglas-Llabrés, Cristina Bouzas, Oscar Pastor, Lucía Ugarriza, Isabel Llompart, Karla Cevallos-Ibarra, Antoni Sureda, Josep A. Tur Antioxidants.2023; 12(8): 1554. CrossRef
Correspondence on Letter regarding “Risk factors in nonalcoholic fatty liver disease” Eileen L. Yoon, Dae Won Jun Clinical and Molecular Hepatology.2023; 29(4): 1050. CrossRef
Non-alcoholic fatty liver disease and gut microbial dysbiosis- underlying mechanisms and gut microbiota mediated treatment strategies Muthukumaran Jayachandran, Shen Qu Reviews in Endocrine and Metabolic Disorders.2023; 24(6): 1189. CrossRef
Advancing the global public health agenda for NAFLD: a consensus statement Jeffrey V. Lazarus, Henry E. Mark, Quentin M. Anstee, Juan Pablo Arab, Rachel L. Batterham, Laurent Castera, Helena Cortez-Pinto, Javier Crespo, Kenneth Cusi, M. Ashworth Dirac, Sven Francque, Jacob George, Hannes Hagström, Terry T.-K. Huang, Mona H. Isma Nature Reviews Gastroenterology & Hepatology.2022; 19(1): 60. CrossRef
Vaspin attenuates steatosis-induced fibrosis via GRP78 receptor by targeting AMPK signaling pathway Alina Abdolahi, Zakaria Vahabzadeh, Esmael Izadpanah, Mohammad Raman Moloudi Journal of Physiology and Biochemistry.2022; 78(1): 185. CrossRef
Healthy dietary patterns and metabolic dysfunction-associated fatty liver disease in less-developed ethnic minority regions: a large cross-sectional study Xiaofen Xie, Bing Guo, Xiong Xiao, Jianzhong Yin, Ziyun Wang, Xiaoman Jiang, Jingzhong Li, Lu Long, Junmin Zhou, Ning Zhang, Yuan Zhang, Ting Chen, Baima Kangzhuo, Xing Zhao BMC Public Health.2022;[Epub] CrossRef
Dietary patterns in non-alcoholic fatty liver disease (NAFLD): Stay on the straight and narrow path! Niki Katsiki, Anca Pantea Stoian, Manfredi Rizzo Clínica e Investigación en Arteriosclerosis.2022; 34: S24. CrossRef
Dietary Patterns and Prevalent NAFLD at Year 25 from the Coronary Artery Risk Development in Young Adults (CARDIA) Study Meagan E. Gray, Sejong Bae, Rekha Ramachandran, Nicholas Baldwin, Lisa B. VanWagner, David R. Jacobs, James G. Terry, James M. Shikany Nutrients.2022; 14(4): 854. CrossRef
Impact of SARS-CoV-2 Lockdown on the Preoperative Care Program of Patients Scheduled for Bariatric Surgery Luigi Schiavo, Pietro Calabrese, Silvana Mirella Aliberti, Salvatore Tramontano, Antonio Iannelli, Vincenzo Pilone Nutrients.2022; 14(7): 1488. CrossRef
Renaming NAFLD to MAFLD: Advantages and Potential Changes in Diagnosis, Pathophysiology, Treatment, and Management Fajuan Rui, Hongli Yang, Xinyu Hu, Qi Xue, Yayun Xu, Junping Shi, Jie Li Infectious Microbes and Diseases.2022; 4(2): 49. CrossRef
Dietary patterns in non-alcoholic fatty liver disease (NAFLD): Stay on the straight and narrow path! Niki Katsiki, Anca Pantea Stoian, Manfredi Rizzo Clínica e Investigación en Arteriosclerosis (English Edition).2022; 34: 23. CrossRef
Adherence to Mediterranean Diet and NAFLD in Patients with Metabolic Syndrome: The FLIPAN Study Sofía Montemayor, Catalina M. Mascaró, Lucía Ugarriza, Miguel Casares, Isabel Llompart, Itziar Abete, María Ángeles Zulet, J. Alfredo Martínez, Josep A. Tur, Cristina Bouzas Nutrients.2022; 14(15): 3186. CrossRef
Physiopathology of nonalcoholic fatty liver disease: from diet to nutrigenomics Paola Meneghel, Elisa Pinto, Francesco Paolo Russo Current Opinion in Clinical Nutrition & Metabolic Care.2022; 25(5): 329. CrossRef
Holistic Approach in the Management of Nonalcoholic Fatty Liver Disease Ananta Shrestha, Shrijana Pradhananga Euroasian Journal of Hepato-Gastroenterology.2022; 12(S1): S51. CrossRef
Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD Beom Kyung Kim, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Tuo Lin, Xin M. Tu, Jaclyn Bergstrom, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi N Journal of Hepatology.2022; 77(6): 1482. CrossRef
Implementation of a Whole Food Plant Based Diet in a Food as Prevention Program in a Resource Constrained Environment Subhas C. Ganguli, Lindsey A. Russell, Keith S. Tsoi Journal of Lifestyle Medicine.2022; 12(3): 148. CrossRef
Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review Kiarash Riazi, Mark G. Swain, Stephen E. Congly, Gilaad G. Kaplan, Abdel-Aziz Shaheen Nutrients.2022; 14(21): 4556. CrossRef
Metabolic drivers of non-alcoholic fatty liver disease Kendra K. Bence, Morris J. Birnbaum Molecular Metabolism.2021; 50: 101143. CrossRef
Overview of Non-Alcoholic Fatty Liver Disease (NAFLD) and the Role of Sugary Food Consumption and Other Dietary Components in Its Development Pau Vancells Lujan, Esther Viñas Esmel, Emilio Sacanella Meseguer Nutrients.2021; 13(5): 1442. CrossRef
Integrative Behandlungsansätze bei chronischen Lebererkrankungen Roman Huber Zeitschrift für Komplementärmedizin.2021; 13(02): 14. CrossRef
Serum milk fat globule-EGF factor 8 protein as a potential biomarker for metabolic syndrome Han Ah Lee, Jihwan Lim, Hyung Joon Joo, Young-Sun Lee, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Yoon Tae Jeen, Jong Eun Yeon, Do-Sun Lim, Kwan Soo Byun, Yeon Seok Seo Clinical and Molecular Hepatology.2021; 27(3): 463. CrossRef
Defining comprehensive models of care for NAFLD Jeffrey V. Lazarus, Quentin M. Anstee, Hannes Hagström, Kenneth Cusi, Helena Cortez-Pinto, Henry E. Mark, Michael Roden, Emmanuel A. Tsochatzis, Vincent Wai-Sun Wong, Zobair M. Younossi, Shira Zelber-Sagi, Manuel Romero-Gómez, Jörn M. Schattenberg Nature Reviews Gastroenterology & Hepatology.2021; 18(10): 717. CrossRef
Effect of Nutrition Education in NAFLD Patients Undergoing Simultaneous Hyperlipidemia Pharmacotherapy: A Randomized Controlled Trial Won Myung Lee, Jea Hurn Bae, Young Chang, Sae Hwan Lee, Ji Eun Moon, Soung Won Jeong, Jae Young Jang, Sang Gyune Kim, Hong Soo Kim, Jeong-Ju Yoo, Young Seok Kim Nutrients.2021; 13(12): 4453. CrossRef
Reduction of Visceral Adiposity as a Predictor for Resolution of Nonalcoholic Fatty Liver in Potential Living Liver Donors Sunyoung Lee, Kyoung Won Kim, Jeongjin Lee, Taeyong Park, Hyo Jung Park, Gi‐Won Song, Sung‐Gyu Lee Liver Transplantation.2021; 27(10): 1424. CrossRef
Influence of Dietary Behaviors on Dyslipidemia in Pregnant Women and Its Effects on Physical Development of Fetuses and Infants: A Bidirectional Cohort Study Chenyang Li, Xuening Li, Dan Wu, Qi Chen, Zhe Xiao, Deliang Wen, Lingling Zhai, Lihong Jia Nutrients.2021; 13(10): 3398. CrossRef
The effects of Ramadan intermittent fasting on liver function in healthy adults: A systematic review, meta-analysis, and meta-regression MoezAlIslam Faris, Haitham Jahrami, Dana Abdelrahim, Nicola Bragazzi, Ahmed BaHammam Diabetes Research and Clinical Practice.2021; 178: 108951. CrossRef
Dieckol Decreases Caloric Intake and Attenuates Nonalcoholic Fatty Liver Disease and Hepatic Lymphatic Vessel Dysfunction in High-Fat-Diet-Fed Mice Kyung-A Byun, Seyeon Oh, Myeongjoo Son, Chul-Hyun Park, Kuk Hui Son, Kyunghee Byun Marine Drugs.2021; 19(9): 495. CrossRef
Hepatic-Metabolite-Based Intermittent Fasting Enables a Sustained Reduction in Insulin Resistance in Type 2 Diabetes and Metabolic Syndrome Markus Rohner, Robert Heiz, Simon Feldhaus, Stefan R. Bornstein Hormone and Metabolic Research.2021; 53(08): 529. CrossRef
Fasting, Nutrition and Weight Loss: An Approach to Refine Non-Alcoholic Fatty Liver Disease Galal A. AL-SAMHARI, Gaber M. AL-MUSHIKI, Rashi TAMRAKAR, Gibirima ABDULLAHI, YUE-Dong LIN, XIAN-Yan TANG Journal of Nutritional Science and Vitaminology.2021; 67(6): 366. CrossRef
KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease Seong Hee Kang, Hye Won Lee, Jeong-Ju Yoo, Yuri Cho, Seung Up Kim, Tae Hee Lee, Byoung Kuk Jang, Sang Gyune Kim, Sang Bong Ahn, Haeryoung Kim, Dae Won Jun, Joon-Il Choi, Do Seon Song, Won Kim, Soung Won Jeong, Moon Young Kim, Hong Koh, Sujin Jeong, Jin-Wo Clinical and Molecular Hepatology.2021; 27(3): 363. CrossRef
The Troubling Link Between Non-alcoholic Fatty Liver Disease (NAFLD) and Extrahepatic Cancers (EHC) Ajit Venniyoor, Abdul Aziz Al Farsi, Bassim Al Bahrani Cureus.2021;[Epub] CrossRef
First
Prev
